Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Moderna to Have One of Industry’s Biggest Pipelines in 5 Years, Oncology Might Make Up 30% of Sales: CEO
Moderna will morph into a company that boasts “one of the biggest pipelines in the industry” in five years’ time, with 100 or 150 products expected to be in development, a big jump from the current 46, CEO Stephane Bancel…
To read the full story
Related Article
- Will Moderna See Multiple Japan Filings in the Coming Years? 5 Late-Stage Assets in Pipeline
June 19, 2025
- Moderna CEO Maintains Future Vision for Product Mix despite R&D Cutback, Eyes Leap with Flu-COVID Shot
October 18, 2024
- Moderna Looks to Start Japan Production of mRNA Vaccines around 2027
April 20, 2023
- Moderna Probing Correlations between Spikevax Adverse Reactions and Immune Response: SVP
October 7, 2022
- Moderna in Talks with Govt on Building Vaccine Plant in Japan: CEO
September 16, 2022
BUSINESS
- Bayer Regulatory Chief Hails Japan’s Review System, Flexibility on PI Waivers
May 28, 2026
- Asahi Kasei Licenses ADC Technology from Noguchi Institute
May 28, 2026
- Kissei Files Rigel’s AML Drug Olutasidenib in Japan
May 28, 2026
- Japan OTC Market Falls 2.4% in April amid Weaker Inbound Demand: Intage
May 28, 2026
- Astellas Sees Sales Decline through FY2029 on Xtandi LOE, Maps 200 Billion Yen Cuts in 5 Years
May 27, 2026
Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…